NCT04144569招募中2 期
the Effectiveness and Safety Study on PD-1 Combined With Pyrotinib for First-line Chemotherapy Failed HER2 Insertion Mutation Advanced Non-small Cell Lung Cancer
Yongchang Zhang1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年1月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced non-small cell lung cancer confirmed by histology or cytology
- •HER2 insertion mutation-positive
- •Failure with first-line standard chemotherapy
- •with measurable lesions.
排除标准
- •no measurable tumor lesions
- •Patients received PD-1 or Pyrotinib before
研究组 & 干预措施
PD-1 Combined With Pyrotinib
Experimental
PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
干预措施: PD-1 Combined With Pyrotinib (Drug)
结局指标
主要结局
PFS
时间窗: Approximately 1 years
Progression free survival
次要结局
- ORR(Approximately 1 years)
- OS(Approximately 1 years)
研究者
Yongchang Zhang
Professor
Hunan Province Tumor Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid CancerThyroid CancerNCT05659186West China Hospital20
尚未招募
2 期
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical StudySquamous Non-Small Cell Lung Cancer SqNSCLCNCT06747169Jian-Guo Zhou, MD, PhD32
进行中（未招募）
2 期
PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaMetastatic MelanomaNCT05034536Massachusetts General Hospital36
已完成
2 期
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell TransplantationMultiple MyelomaNCT01067287Beth Israel Deaconess Medical Center35
撤回
2 期
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven CriteriaHepatocellular CarcinomaNCT03775707Shi Ming